Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Developing a core outcome set for the NeuroPoint Alliance Quality Outcomes Database Pediatric Tumor Surgery Registry: a modified Delphi study.

Journal of neuro-oncology·2026
Same author

Binational patterns in use of Food is Medicine among Mexican immigrants.

Frontiers in nutrition·2026
Same author

Oropouche virus RNA persistence and antibody kinetics: a multi-specimen, genomic and serological analysis.

Journal of travel medicine·2026
Same author

Generative AI for climate governance and acceptability-constrained policy design.

npj climate action·2026
Same author

Assessing the Implementation of Shared Decision-Making in Primary Care: A Study With Unannounced Standardized Patients.

Journal of evaluation in clinical practice·2026
Same author

Clinical and pathologic correlations of machine learning quantification of Aβ deposits across 3 brain regions of decedents with Alzheimer disease.

Journal of neuropathology and experimental neurology·2026

Related Experiment Video

Updated: Jun 2, 2026

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Vitamin K antagonists--current concepts and challenges.

Hayan Moualla1, David Garcia

  • 1Division of Hematology and Oncology, University of New Mexico, USA.

Thrombosis Research
|May 17, 2011
PubMed
Summary
This summary is machine-generated.

Vitamin K antagonists (VKAs) are essential for outpatient anticoagulation. Improved monitoring and understanding of interactions make VKAs safer, with future innovations promising enhanced management for thromboembolism risk.

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Related Experiment Videos

Last Updated: Jun 2, 2026

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Thrombosis Management

Background:

  • Vitamin K antagonists (VKAs) have long been the primary oral anticoagulation therapy.
  • VKAs require close monitoring due to a narrow therapeutic index and inter-individual response variability.
  • Despite challenges, advancements have improved VKA safety and patient burden.

Purpose of the Study:

  • To review the established role and evolving management of Vitamin K antagonists in anticoagulation.
  • To highlight the impact of monitoring systems and interaction awareness on VKA therapy.
  • To discuss future directions in anticoagulation management.

Main Methods:

  • Literature review of anticoagulation therapies.
  • Analysis of VKA monitoring systems and drug/dietary interactions.
  • Exploration of emerging oral anticoagulants and personalized dosing.

Main Results:

  • VKAs remain a cornerstone of outpatient anticoagulation due to practical dosing.
  • Specialized monitoring and better understanding of interactions have enhanced VKA safety.
  • Individualized VKA response necessitates careful management.

Conclusions:

  • Current anticoagulation management relies heavily on VKAs, with ongoing improvements in safety and usability.
  • Future anticoagulation strategies may involve novel oral agents and genomic-guided dosing.
  • Enhanced patient management for thromboembolism risk is anticipated with new therapeutic approaches.